FDA Releases New Guidance on Real-World Drug Safety Studies
Published Date: 3/4/2026
Notice
Summary
The FDA just released new rules to help drug makers and researchers use real-world data to check medicine safety better and faster. This update affects anyone doing non-interventional studies on drugs, vaccines, or biologics, replacing older guidance and aiming to make safety checks smoother without extra costs. The new guidance is effective now and encourages clear planning, smart data use, and honest reporting to keep medicines safe for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final M14 Guidance Available
The FDA issued the final ICH M14 guidance on March 4, 2026 for non-interventional studies that use real-world data to assess the safety of medicines (drugs, vaccines, and biological products). The guidance lays out recommended principles for planning, designing, analyzing, reporting, and submitting these studies.
Enhanced Methodology and Reporting Guidance
The final guidance includes comprehensive recommendations and enhanced discussion on Initial Design and Feasibility, the Conceptual Framework, quantitative bias analysis, and protocol development including characteristics and types of data sources. These revisions followed public comment and were incorporated before endorsement in September 2025.
Older Guidance Withdrawn and Draft Finalized
The final M14 guidance finalizes the July 5, 2024 draft and, upon publication, FDA intends to withdraw the prior guidance titled "Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data" published May 14, 2013. The final guideline was endorsed by ICH regulatory agencies in September 2025.
No New Paperwork Burden
The guidance contains no new collection of information under the Paperwork Reduction Act, and it references previously approved FDA information collections (for example, OMB control numbers 0910-0014, 0910-0001, and others).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04252 — E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released new rules for drug companies on how to track and report safety info after a drug is approved. This update includes fresh ways to use data from places like social media and patient programs to keep medicines safe. Drug makers should get ready to follow these clearer, modern rules starting now, helping protect patients without extra costs.
Next: 2026-04255 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V SAPPHIRE
The Maritime Administration is checking if the foreign-built small passenger vessel M/V SAPPHIRE can be used for U.S. coastwise trade without hurting American shipbuilders or businesses. They want your thoughts by April 3, 2026, before making a decision. This affects companies using small passenger vessels and could impact the market for U.S.-built boats.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in